CALIXAR Collaborates with VirPath to Develop H1N1 Vaccine
CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.
CALIXAR, a start-up company providing services focused on membrane proteins, and VirPath, an academic lab specializing in the study of influenza viruses, announced on Sept. 23, 2014 the use of new manufacturing techniques to develop an influenza A (H1N1) vaccine.
The partners’ new formulation of vaccine antigens is designed to prevent influenza A (H1N1) virus, or pandemic flu. The formulation showed improved performance compared to other vaccines on the market. CALIXAR developed the technology and chemistry to split the virus’ membranes. VirPath’s egg-derived antigens formulations, which were extracted with CALIXAR’s technology, are at least six times more active than currently marketed vaccines, in terms of hemagglutinin immunogenicity and in-vivo protection, according to a CALIXAR press release.
“We will offer the influenza technology for licensing early 2015. We are also looking at other applications in the vaccine industry using the same chemistry and biochemistry approaches,” said Chairman and CEO of CALIXAR, DR. Emmanuel Dejean, in the release.
Source: CALIXAR
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
